title: Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone.
abstract: OBJECTIVE
  This study aimed to assess the efficacy of aripiprazole for the management of cognitive impairments and hyperprolactinemia in patients with schizophrenia on a stable dose of risperidone.
  
  
  METHODS
  Thirty-five subjects stabilized on risperidone (3-6 mg/day) for a minimum of 3 months were enrolled in a double-blind, placebo-controlled phase for 12 weeks and an open-label phase for another 12 weeks. Subjects were randomly assigned to receive 10 mg/day aripiprazole (n=17) or placebo (n=18). Over the following 12 weeks, the the aripiprazole group received a flexible dose of aripiprazole while tapering risperidone. At baseline, week 12, and week 24, subjects were evaluated using the Positive and Negative Syndrome Scale (PANSS), Extrapyramidal Syndrome Rating Scale (ESRS), and standardized neuropsychological assessments. Serum prolactin levels were checked at baseline, week 1, week 2, and week 24.
  
  
  RESULTS
  The mean change in total PANSS and cognitive function test scores between baseline and endpoint were similar in the aripiprazole and placebo groups. Scores on the ESRS and negative subscale of PANSS differed significantly between groups in both phases of the study (p<0.05), indicating a positive effect of aripiprazole. Compared with placebo, aripiprazole significantly reduced mean baseline serum prolactin levels within 1 week (p=0.015).
  
  
  CONCLUSIONS
  Adjunctive treatment with and switching to aripiprazole were not associated with improved cognitive function in patients with schizophrenia receiving risperidone; however, aripiprazole treatment decreased negative symptoms and risperidone-induced motor side effects and lowered serum prolactin levels.
authors.affiliation: Department of Psychiatry, Inje University Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
authors.forename: Bong Ju
authors.initials: BJ
authors.lastname: Lee
authors.forename: Seung Ju
authors.initials: SJ
authors.lastname: Lee
authors.forename: Min Kyung
authors.initials: MK
authors.lastname: Kim
authors.forename: Jung Goo
authors.initials: JG
authors.lastname: Lee
authors.forename: Sung Woo
authors.initials: SW
authors.lastname: Park
authors.forename: Gyung Mee
authors.initials: GM
authors.lastname: Kim
authors.forename: Young Hoon
authors.initials: YH
authors.lastname: Kim
keywords: Aripiprazole; Cognition; Prolactin; Risperidone; Schizophrenia
references.citation: Schizophr Res. 2012 Mar;135(1-3):72-8
references.pmid: 22226902
references.citation: J Psychopharmacol. 2007 Jun;21(4):421-7
references.pmid: 17092979
references.citation: Psychol Med. 2011 Feb;41(2):225-41
references.pmid: 20836900
references.citation: Schizophr Res. 2009 Feb;107(2-3):218-22
references.pmid: 19038534
references.citation: J Clin Psychopharmacol. 2007 Dec;27(6):639-61
references.pmid: 18004132
references.citation: Am J Psychiatry. 2002 Jun;159(6):1018-28
references.pmid: 12042192
references.citation: Psychiatry Investig. 2012 Jun;9(2):166-73
references.pmid: 22707968
references.citation: Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33
references.pmid: 18831971
references.citation: Int Clin Psychopharmacol. 2007 Mar;22(2):63-8
references.pmid: 17293705
references.citation: Psychiatr Danub. 2010 Jun;22(2):211-20
references.pmid: 20562749
references.citation: J Clin Psychiatry. 2006 Oct;67(10):e12
references.pmid: 17107235
references.citation: J Pharmacol Exp Ther. 2002 Jul;302(1):381-9
references.pmid: 12065741
references.citation: Am J Psychiatry. 2007 Sep;164(9):1404-10
references.pmid: 17728426
references.citation: Clin Pract Epidemiol Ment Health. 2008 Oct 29;4:24
references.pmid: 18959801
references.citation: CNS Drugs. 2009 Sep;23(9):773-80
references.pmid: 19689167
references.citation: Int J Neuropsychopharmacol. 2005 Sep;8(3):457-72
references.pmid: 15784157
references.citation: J Psychopharmacol. 2012 Jun;26(6):806-12
references.pmid: 21616975
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):161-8
references.pmid: 21047544
references.citation: Eur J Pharmacol. 2004 Jun 16;493(1-3):75-83
references.pmid: 15189766
references.citation: Eur J Pharmacol. 2002 Apr 26;441(3):137-40
references.pmid: 12063084
references.citation: Neuropsychopharmacology. 2012 Feb;37(3):660-8
references.pmid: 22048460
references.citation: Psychiatry Clin Neurosci. 2009 Feb;63(1):73-81
references.pmid: 19154213
references.citation: Schizophr Bull. 1987;13(2):261-76
references.pmid: 3616518
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1495-9
references.pmid: 20732372
references.citation: J Psychopharmacol. 2004 Sep;18(3):375-83
references.pmid: 15358981
references.citation: J Sex Med. 2007 Sep;4(5):1468-78
references.pmid: 17727354
references.citation: J Clin Psychopharmacol. 2010 Oct;30(5):596-9
references.pmid: 20814333
references.citation: Pharmacopsychiatry. 2010 Mar;43(2):50-7
references.pmid: 20336597
references.citation: J Clin Psychiatry. 2009 Oct;70(10):1348-57
references.pmid: 19906340
references.citation: Clin Neuropharmacol. 2009 Sep-Oct;32(5):243-9
references.pmid: 19620849
references.citation: Curr Drug Metab. 2008 Jun;9(5):410-8
references.pmid: 18537577
references.citation: Schizophr Res. 2005 Jul 15;76(2-3):247-65
references.pmid: 15949657
references.citation: Eur J Pharmacol. 2004 Jan 1;483(1):45-53
references.pmid: 14709325
references.citation: Pharmacotherapy. 2009 Jan;29(1):64-73
references.pmid: 19113797
references.citation: Hum Psychopharmacol. 2010 Mar;25(2):116-25
references.pmid: 20196179